An FDA advisory panel has narrowly recommended that the Food and Drug Administration reclassify four popular peptides, including one promoted by Joe Rogan, paving the way for certain pharmacies to legally dispense them.
The decision came after an intense, 11-hour meeting where committee members reviewed data on unapproved peptides BPC-157, KPV, TB-500, and MOTs-C. They also heard testimony from healthcare professionals, patients, and clinics. Ultimately, the panel voted eight to six, with one abstention, to add three of the peptides to the FDA's bulk list, allowing compounding pharmacies to create custom medications. The fourth peptide, MOTs-C, received a seven-to-five vote in favor with two abstentions. The committee, which includes members with ties to peptide businesses and telehealth, is set to review three more peptides on Friday.
Peptide therapies have surged in popularity, fueled by endorsements from podcasters, wellness influencers, and even public figures like Robert F. Kennedy Jr. These substances, essentially smaller versions of proteins, are marketed for a wide range of benefits—from skin and hair improvements to gut health and injury recovery—despite a significant lack of robust scientific evidence. Many peptides currently circulate in an unregulated "gray market," especially after the Biden administration banned compounding pharmacies from producing 20 peptides due to safety concerns last year. While legally sold online for "research use only," their marketing often implies human consumption, with major suppliers in China and India.
During the meeting, the FDA's own scientists recommended against allowing compounding pharmacies to produce any of the considered peptides, citing insufficient evidence of safety and effectiveness. Conversely, proponents argued that allowing U.S. compounding pharmacies to produce them under prescription would offer patients safer, regulated alternatives. Anant Vinjamoori, chief medical officer at telehealth provider Hims & Hers, acknowledged the limited evidence for BPC-157 but urged the panel not to dismiss it entirely, as his company is preparing to launch peptide treatments.
Among the peptides discussed, BPC-157 and TB-500 are notably popular, often combined as a "Wolverine stack" for injury recovery. BPC-157 is also being considered for ulcerative colitis, though the World Anti-Doping Agency flags it as a potential risk to athletes due to limited human studies. While some healthcare providers shared concerns about patients obtaining dangerous, illicitly laced products from the gray market, others warned that FDA approval could create new risks and confusion. Critics argued that legalizing these peptides, even for compounding, sends a misleading message of FDA endorsement and that a gray market would likely persist.
For now, the panel's votes are recommendations, and a formal FDA decision is not expected for several months. Some committee members who voted against the reclassification expressed concerns about unknown safety profiles and the potential for public confusion, likening the situation to opening "Pandora's box."
